U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CPG Sec 540.475 Snapper - Labeling
  1. Search for FDA Guidance Documents

COMPLIANCE POLICY GUIDE (CPG)

CPG Sec 540.475 Snapper - Labeling October 1980

Final
Issued by:
Guidance Issuing Office
Office of Inspections and Investigations
Human Foods Program

BACKGROUND:

The name "red snapper" has been preempted by many years of consistent consumer usage as meaning only the fish, Lutjanus campechanus. Because of the high esteem in which this fish is held by consumers, and the relatively limited catch, there have been numerous attempts to substitute other, less expensive fishes for this species. Substituted less desirable species have included members of the family Lutjanidae, groupers, a number of West Coast rockfishes of the genus Sebastes, and other species. The West Coast rockfishes have, until relatively recently, been distributed mostly locally, and thus have been beyond the reach of the Federal Food, Drug, and Cosmetic Act. Some of the States on the Pacific Coast have officially sanctioned "red snapper" as an alternative name for such members of the Sebastes genus, although these fishes are quite different in appearance, flavor, and texture, and are generally regarded by consumers familiar with Lutjanus campechanus as inferior.

POLICY:

The labeling or sale of any fish other than Lutjanus campechanus as "red snapper" constitutes a misbranding in violation of the Federal Food, Drug, and Cosmetic Act.

Issued: 10/1/80


Submit Comments

Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All comments should be identified with the title of the guidance.

Back to Top